Bannerbild German Brest Group

Results of an interim analysis from KATHERINE trial

17.12.2018

We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

The KATHERINE study aimed to investigate whether adjuvant T-DM1 was more effective than trastuzumab in patients with HER2-positive primary breast cancer who have received neoadjuvant chemotherapy including trastuzumab and have residual invasive disease after surgery. A total of 1486 patients (743 in the T-DM1 group and 743 in the trastuzumab group) were included in the interim analysis. An invasive disease or death had occurred in 91 patients in the T-DM1 group and in 165 in the trastuzumab group. 3-years invasive disease-free survival was significantly higher in the T-DM1 group than in the trastuzumab group (88.3% vs 77.0% respectively, hazard ratio 0.50 [95%CI 0.39-0.64]; p<0.001). Thus, the risk of recurrence of invasive disease or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant chemotherapy plus HER2-targeted therapy. In terms of toxicity, a higher percentage of patients had adverse events in the T-DM1 group than in the trastuzumab group.

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018 Dec 5. [Epub ahead of print].

Link in PubMed

News

  • 15.11.2018 Save the Date: AGO-Mamma 2019

    Save the Date: AGO-Mamma 2019

    Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.

    Mehr ...
  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...
  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd